Browsing publications by Dr Jill Hunter

Newcastle AuthorsTitleYearFull text
Dr Jacqueline Butterworth
Dr Jill Hunter
Helene Sellier
Dr Dina Tiniakos
Dr Simon Cockell
et al.
A RelA(p65) Thr505 phospho-site mutation reveals an important mechanism regulating NF-kB dependent liver regeneration and cancer2016
Dr Jill Hunter
Jack Leslie
Professor Neil Perkins
c-Rel and its many roles in cancer: an old story with new twists2016
Dr Jill Hunter
Professor Neil Perkins
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma2016
Dr Ashleigh Herriott
Dr Susan Tudhope
Gesa Junge
Natalie Rodrigues
Dr Miranda Patterson
et al.
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia2015
Dr Jill Hunter
Dr Jacqueline Butterworth
Helene Sellier
Huw Thomas
Dr Christopher Bacon
et al.
The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma2015
Dr Adeline Ledoux
Dr Jill Hunter
Professor Neil Perkins
Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy2014
Dr Jill Hunter
Dr Jacqueline Butterworth
Professor Neil Perkins
Professor Melissa Bateson
Dr Claire Richardson
et al.
Using body temperature, food and water consumption as biomarkers of disease progression in mice with Eμ-myc lymphoma2014
Dr Jill Hunter
Dr Elaine Willmore
Dr Julie Irving
Dr Stephany Veuger
Emeritus Professor Barbara Durkacz
et al.
NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-0146992012
Dr Susan Tudhope
Dr Evan Mulligan
Dr Jill Hunter
Dr Helen Marr
Emeritus Professor Barbara Durkacz
et al.
P B S-1086, a "Pan-Rel" Inhibitor, Decreases Viability of Chronic Lymphocytic Leukemia Cells2012